548 Odcinki

  1. Deriving Rare Disease Therapies from Human Plasma

    Opublikowany: 18.10.2017
  2. Learning to Live with Purpose

    Opublikowany: 11.10.2017
  3. A Mother's Race to Find a Treatment for Her Daughter's Ultra-Rare Condition

    Opublikowany: 4.10.2017
  4. Screening for Rare Diseases

    Opublikowany: 27.09.2017
  5. A Look at the Changing World of Work for People with a Chronic Illness

    Opublikowany: 20.09.2017
  6. Aligning Interests in Rare Disease Partnerships

    Opublikowany: 13.09.2017
  7. A Veteran Venture Capitalist Discusses Investing in Rare Disease Drug Development

    Opublikowany: 6.09.2017
  8. A Patient Group Crafts Guidelines for Working with Pharma

    Opublikowany: 30.08.2017
  9. Bringing Innovation to Business Models for Rare Disease Drug Development

    Opublikowany: 23.08.2017
  10. Rethinking Accessibility and Dependency

    Opublikowany: 16.08.2017
  11. How Simon Wheatcroft, Blinded by a Rare Disease, Became an Ultramarathoner

    Opublikowany: 9.08.2017
  12. Spark Hoping Its Luxturna Will Become First FDA-Approved Gene Therapy

    Opublikowany: 2.08.2017
  13. What Rare Patient-Investors Can Learn From Venture Capitalists

    Opublikowany: 26.07.2017
  14. Novel Effort Delivers Failed DMD Drug to Former Clinical Trial Participants

    Opublikowany: 19.07.2017
  15. Centogene Seeks to Deliver Diagnoses to Rare Disease Patients Early

    Opublikowany: 12.07.2017
  16. Albireo Advances Pipeline for Rare Liver and Gastrointestinal Diseases

    Opublikowany: 5.07.2017
  17. aTyr Pharma Seeks to Modulate Activity in FSHD and Other Rare Disease

    Opublikowany: 28.06.2017
  18. Summit Pursues A Different Approach to Treating Duchenne

    Opublikowany: 21.06.2017
  19. Delivering Enzyme Replacement Therapies Across the Blood-Brain Barrier

    Opublikowany: 14.06.2017
  20. Sangamo Advances Gene Editing Therapies for Multiple Rare Diseases into the Clinic

    Opublikowany: 7.06.2017

21 / 28

RARECast is a Global Genes podcast hosted by award-winning journalist Daniel Levine. It focuses on the intersection of rare disease with business, science, and policy.

Visit the podcast's native language site